¼¼°èÀÇ ÀÓ»ó½ÃÇè ¸ÅĪ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå
Clinical Trials Matching Software
»óǰÄÚµå : 1786000
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 276 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,229,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,687,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ÀÓ»ó½ÃÇè ¸ÅĪ ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº 2030³â±îÁö 3¾ï 7,950¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1¾ï 8,710¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ÀÓ»ó½ÃÇè ¸ÅĪ ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº 2030³â¿¡´Â 3¾ï 7,950¸¸ ´Þ·¯¿¡ ´ÞÇϸç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 12.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ À¥ ¹× Ŭ¶ó¿ìµå ±â¹Ý ¹èÆ÷´Â CAGR 14.7%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 2¾ï 4,780¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿ÂÇÁ·¹¹Ì½º ¹èÆ÷ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 9.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 5,100¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 17.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀÓ»ó½ÃÇè ¸ÅĪ ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº 2024³â¿¡ 5,100¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 8,140¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 17.2%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 8.9%¿Í 11.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 9.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÀÓ»ó½ÃÇè ¸ÅĪ ¼ÒÇÁÆ®¿þ¾î ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÀÓ»ó½ÃÇè ¸ÅĪ ¼ÒÇÁÆ®¿þ¾î°¡ ȯÀÚ µî·ÏÀ» º¯È­½ÃŰ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

ÀÓ»ó½ÃÇè ¸ÅĪ ¼ÒÇÁÆ®¿þ¾î´Â ÀΰøÁö´É(AI)°ú ºòµ¥ÀÌÅÍ ºÐ¼®À» Ȱ¿ëÇÏ¿© Àû°Ý Âü°¡ÀÚ¿Í °ü·Ã ÀÓ»ó½ÃÇèÀ» ¿¬°áÇÔÀ¸·Î½á ȯÀÚ ¸ðÁý¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ È¯ÀÚ µî·Ï ¹æ¹ýÀº ºñÈ¿À²ÀûÀÎ °æ¿ì°¡ ¸¹À¸¸ç, ±× °á°ú ÀÓ»ó½ÃÇè ÀÏÁ¤ÀÌ Áö¿¬µÇ°Å³ª Å»¶ô·üÀÌ ³ô¾ÆÁö´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¸ÅĪ ¼ÒÇÁÆ®¿þ¾î´Â ÀüÀÚÀǹ«±â·Ï(EHR), À¯ÀüÀÚ µ¥ÀÌÅÍ, ȯÀÚ º¸°í °á°ú¸¦ ºÐ¼®ÇÏ¿© ÀûÇÕÇÑ Èĺ¸ÀÚ¸¦ ½Ç½Ã°£À¸·Î ½Äº°ÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇÕ´Ï´Ù. ÀÌ ±â¼úÀº ȯÀÚ ¼ö°¡ Á¦ÇѵǾî ÀÖÀ¸¸ç, Àû°Ý ȯÀÚ¸¦ ã±â°¡ ¾î·Á¿î Èñ±ÍÁúȯ ÀÓ»ó½ÃÇè¿¡ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ¶ÇÇÑ È¯ÀÚ Áß½ÉÀÇ ÀÓ»ó½ÃÇèÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÚµ¿ ¸ÅĪ ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ȯÀÚº° ÀÇ·á ÇÁ·ÎÆÄÀÏÀ» ±â¹ÝÀ¸·Î ÇÑ Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

÷´Ü ÀÓ»ó½ÃÇè ¸ÅĪ ¼ÒÇÁÆ®¿þ¾îÀÇ ÁÖ¿ä Æ¯Â¡Àº ¹«¾ùÀΰ¡?

ÃֽŠÀÓ»ó½ÃÇè ¸ÅĪ ¼ÒÇÁÆ®¿þ¾î´Â ÷´Ü ¾Ë°í¸®Áò, ÀÚ¿¬ ¾ð¾î ó¸®(NLP), AI ±â¹Ý ºÐ¼®À» ÅëÇØ ȯÀÚ ½Äº° ¹× µî·ÏÀ» È¿À²È­ÇÕ´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý Ç÷§ÆûÀº º´¿ø µ¥ÀÌÅͺ£À̽º¿ÍÀÇ ¿øÈ°ÇÑ ÅëÇÕÀ» ¿ëÀÌÇÏ°Ô Çϰí, ÀÓ»ó½ÃÇè ÀÚ°Ý ±âÁØÀ» ½Ç½Ã°£À¸·Î ¾÷µ¥ÀÌÆ®ÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ȯÀÚ Âü¿©Çü Æ÷Åаú ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼Ǵ ȯÀÚ°¡ ÀÚ½ÅÀÇ »óÅÂ, À§Ä¡, Ä¡·á ¼±È£µµ¿¡ µû¶ó °ü·Ã ÀÓ»ó½ÃÇèÀ» °Ë»öÇÒ ¼ö ÀÖµµ·Ï ÇÔÀ¸·Î½á ȯÀÚ ¸ðÁýÀ» ´õ¿í °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºí·ÏüÀÎ ±â¼úÀ» µµÀÔÇÏ¿© µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã¿Í º¸¾ÈÀ» °³¼±Çϰí, µðÁöÅÐ ¸ÅĪ Ç÷§Æû¿¡ ´ëÇÑ È¯ÀÚÀÇ ½Å·Ú¸¦ È®º¸Çϱâ À§ÇØ ºí·ÏüÀÎ ±â¼úÀ» µµÀÔÇß½À´Ï´Ù. AI¿Í ¿¹Ãø ¸ðµ¨¸µÀÌ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó ÀÓ»ó½ÃÇè ¸ÅĪ ¼ÒÇÁÆ®¿þ¾îÀÇ Á¤È®µµ°¡ Á¡Á¡ ´õ ³ô¾ÆÁ® ½ºÅ©¸®´× ½ÇÆÐ¸¦ ÃÖ¼ÒÈ­Çϰí Àüü ÀÓ»ó½ÃÇèÀÇ È¿À²¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

¸ÅĪ ¼ÒÇÁÆ®¿þ¾î°¡ ÀÓ»ó½ÃÇèÀÇ ´Ù¾ç¼º°ú Æ÷¿ë¼ºÀ» ¾î¶»°Ô °³¼±Çϰí Àִ°¡?

Àӻ󿬱¸ÀÇ °¡Àå Å« °úÁ¦ Áß Çϳª´Â ÀÓ»ó½ÃÇè Áý´ÜÀÇ ´Ù¾çÇÑ ´ëÇ¥¼ºÀ» È®º¸ÇÏ´Â °ÍÀÔ´Ï´Ù. ¸ÅĪ ¼ÒÇÁÆ®¿þ¾î´Â ¾Æ¿ô¸®Ä¡ Ȱµ¿À» È®ÀåÇϰí, ÃæºÐÈ÷ ´ëÇ¥µÇÁö ¾ÊÀº °èÃþ¿¡¼­ ÀÚ°ÝÀ» °®Ãá Âü°¡ÀÚ¸¦ ½Äº°ÇÔÀ¸·Î½á ÀÌ ¹®Á¦¸¦ ÇØ°áÇϰí ÀÖ½À´Ï´Ù. AI ±â¹Ý ºÐ¼®Àº °Ç°­ÀÇ »çȸÀû °áÁ¤ ¿äÀÎÀ» ÆÄ¾ÇÇÏ´Â µ¥ µµ¿òÀÌ µÇ¸ç, ÀÎÁ¾Àû, Áö¿ªÀû, °æÁ¦Àû ¿äÀÎÀ» °í·ÁÇÑ Å¸°ÙÆÃµÈ äÅà Àü·«À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¼ÒÇÁÆ®¿þ¾î ÇÁ·Î¹ÙÀÌ´õ, ¿ËÈ£ ´Üü, Áö¿ª ÀÇ·á ¼¾ÅÍ °£ÀÇ ÆÄÆ®³Ê½ÊÀ» ÅëÇØ ÀÓ»ó½ÃÇè ±âȸ¿¡ ´ëÇÑ °øÆòÇÑ Á¢±ÙÀ» ´õ¿í º¸ÀåÇϰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè µî·ÏÀÇ °ÝÂ÷¸¦ ÁÙÀÓÀ¸·Î½á ¸ÅĪ ¼ÒÇÁÆ®¿þ¾î´Â °Ç°­ ÇüÆò¼ºÀ» ÁõÁøÇϰí ÀÓ»ó ¿¬±¸ °á°úÀÇ ÀϹÝÈ­ °¡´É¼ºÀ» Çâ»ó½ÃŰ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

ÀÓ»ó½ÃÇè ¸ÅĪ ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

ÀÓ»ó½ÃÇè ¸ÅĪ ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀÇ ¼ºÀåÀº È¿À²ÀûÀΠȯÀÚ ¸ðÁý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, AI ±â¹Ý ºÐ¼®ÀÇ ¹ßÀü, ºÐ»êÇü ÀÓ»ó½ÃÇèÀÇ È®´ë µî ¸î °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ÀÓ»ó½ÃÇè ÀÏÁ¤À» ´ÜÃàÇØ¾ß ÇÏ´Â Á¦¾à»çµéÀº Áö¿¬À» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ´Â ÀÚµ¿ µî·Ï ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹µµ ÀÓ»ó½ÃÇèÀÇ ´Ù¾ç¼º È®´ë¸¦ ¿ËÈ£Çϰí ÀÖÀ¸¸ç, ȯÀÚ Å¸°ÙÆÃÀ» ÃËÁøÇÏ´Â ¼ÒÇÁÆ®¿þ¾îÀÇ Ã¤ÅÃÀ» Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚ¸¦ Á÷Á¢ ¸ðÁýÇÏ´Â ¸ðµ¨ÀÇ ºÎ»óÀ¸·Î ¸ð¹ÙÀÏ Ä£È­ÀûÀÎ ¸ÅĪ Ç÷§Æû¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á°¡ Áö¼ÓÀûÀ¸·Î È®»êµÊ¿¡ µû¶ó AI¸¦ Ȱ¿ëÇÑ ¸ÅĪ ¼Ö·ç¼ÇÀÇ È°¿ëÀÌ È®´ëµÇ°í, ½ÃÀå ¼ºÀåÀÌ ´õ¿í °¡¼ÓÈ­µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

¹èÆ÷(À¥ ¹× Ŭ¶ó¿ìµå ±â¹Ý ¹èÆ÷, ¿ÂÇÁ·¹¹Ì½º ¹èÆ÷), ÃÖÁ¾»ç¿ëÀÚ(Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ ÃÖÁ¾»ç¿ëÀÚ, CRO ÃÖÁ¾»ç¿ëÀÚ, ÀÇ·á±â±â ±â¾÷ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Clinical Trials Matching Software Market to Reach US$379.5 Million by 2030

The global market for Clinical Trials Matching Software estimated at US$187.1 Million in the year 2024, is expected to reach US$379.5 Million by 2030, growing at a CAGR of 12.5% over the analysis period 2024-2030. Web & Cloud-based Deployment, one of the segments analyzed in the report, is expected to record a 14.7% CAGR and reach US$247.8 Million by the end of the analysis period. Growth in the On-Premise Deployment segment is estimated at 9.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$51.0 Million While China is Forecast to Grow at 17.2% CAGR

The Clinical Trials Matching Software market in the U.S. is estimated at US$51.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$81.4 Million by the year 2030 trailing a CAGR of 17.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.9% and 11.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.9% CAGR.

Global Clinical Trials Matching Software Market - Key Trends & Drivers Summarized

Why Is Clinical Trials Matching Software Transforming Patient Enrollment?

Clinical trials matching software is revolutionizing patient recruitment by leveraging artificial intelligence (AI) and big data analytics to connect eligible participants with relevant clinical studies. Traditional patient enrollment methods often suffer from inefficiencies, resulting in delayed trial timelines and high dropout rates. Matching software addresses these challenges by analyzing electronic health records (EHRs), genetic data, and patient-reported outcomes to identify suitable candidates in real time. This technology is particularly beneficial for rare disease trials, where finding eligible participants is often difficult due to limited patient populations. Additionally, the rise of patient-centric trials is increasing the adoption of automated matching solutions, ensuring that individuals have better access to innovative treatments based on their unique medical profiles.

What Are the Key Features of Advanced Trials Matching Software?

Modern clinical trials matching software incorporates advanced algorithms, natural language processing (NLP), and AI-driven analytics to streamline patient identification and enrollment. Cloud-based platforms facilitate seamless integration with hospital databases, enabling real-time updates on trial eligibility criteria. Patient engagement portals and mobile applications further enhance recruitment by allowing individuals to search for relevant trials based on their condition, location, and treatment preferences. Additionally, blockchain technology is being implemented to improve data privacy and security, ensuring patient trust in digital matching platforms. As AI and predictive modeling continue to evolve, trials matching software is becoming increasingly precise, minimizing screening failures and improving overall trial efficiency.

How Is Matching Software Improving Diversity and Inclusion in Clinical Trials?

One of the biggest challenges in clinical research is ensuring diverse representation in trial populations. Matching software is addressing this issue by expanding outreach efforts and identifying eligible participants from underrepresented demographics. AI-driven analytics help pinpoint social determinants of health, enabling targeted recruitment strategies that account for ethnic, geographic, and economic factors. Partnerships between software providers, advocacy groups, and community health centers are further ensuring equitable access to trial opportunities. By reducing disparities in trial enrollment, matching software is playing a key role in advancing health equity and improving the generalizability of clinical research findings.

What’s Driving the Growth of the Clinical Trials Matching Software Market?

The growth in the clinical trials matching software market is driven by several factors, including the increasing demand for efficient patient recruitment, advancements in AI-driven analytics, and the expansion of decentralized trials. The need for faster trial timelines is encouraging pharmaceutical companies to invest in automated enrollment solutions that minimize delays. Regulatory agencies are also advocating for greater diversity in clinical trials, driving the adoption of software that facilitates targeted patient outreach. Additionally, the rise of direct-to-patient recruitment models is fueling demand for mobile-friendly matching platforms. As precision medicine continues to gain traction, the use of AI-powered matching solutions is expected to expand, further accelerating market growth.

SCOPE OF STUDY:

The report analyzes the Clinical Trials Matching Software market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Deployment (Web and Cloud-based Deployment, On-Premise Deployment); End-Use (Pharmaceutical and Biotechnology Companies End-Use, CROs End-Use, Medical Device Firms End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â